874:HKEXGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H Analysis
Data as of 2026-09-16 - not real-time
MYR 0.06
Latest Price
9/10Risk
Risk Level: High
Executive Summary
At MYR 0.0600, S & F Capital Berhad shows a bullish moving-average alignment, with shorter averages sitting above longer ones. Over a rolling month the price has lost 7.7%. Relative strength is 40.3 — neutral — and the MACD signal is bearish. Recent trading has carved out support near MYR 0.0600 and resistance around MYR 0.0800.
Revenue is growing at 100.6% on a -40.5% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 113.1%, a beta of 1.16 and a maximum drawdown of 31.2%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 91 on the fear-greed composite.
The horizons line up on hold — conviction 2 out of 10.
Revenue is growing at 100.6% on a -40.5% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 113.1%, a beta of 1.16 and a maximum drawdown of 31.2%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 91 on the fear-greed composite.
The horizons line up on hold — conviction 2 out of 10.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading below the 200-day average of 0.06
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading below the 200-day average of 0.06
- 30-day volatility of 113.1%
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- Negative profit margin of -40.5%
- Negative return on equity of -13.3%
- Revenue growth of +100.6%
Key Metrics & Analysis
Financial Health
Revenue Growth100.60%
Profit Margin-40.45%
ROE-13.28%
ROA-3.05%
Debt/Equity60.39
P/B Ratio0.7
Op. Cash FlowMYR2.0M
Free Cash FlowMYR2.9M
Industry P/E30.9
Technical Analysis
TrendBullish
RSI40.3
SupportMYR 0.06
ResistanceMYR 0.08
MA 20MYR 0.07
MA 50MYR 0.06
MA 200MYR 0.06
MACDBearish
VolumeDecreasing
Fear & Greed Index91.46
Valuation
Fair ValueMYR 0.09
GradeFair
TypeBlend
Risk Assessment
Beta1.16
Volatility113.06%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskHigh
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.